Exclusive

Publication

Byline

Location

Clinical Trial: Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex

U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07756138) titled 'Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex' on July 24. Brief Summary: T... Read More


Singapore Clinical Trial: CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

Singapore, Aug. 11 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxe... Read More


Clinical Trial: PENTAGON: MS-Related Disability Worsening and Thalamic Volume Loss

U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07753928) titled 'PENTAGON: MS-Related Disability Worsening and Thalamic Volume Loss' on Aug. 03. Brief Summ... Read More


Singapore Clinical Trial: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Singapore, Aug. 11 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Ad... Read More


Singapore Clinical Trial: Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations

Singapore, Aug. 11 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant... Read More


Clinical Trial: Group Music Therapy for Chronic Pain Management in Active Duty Service Members: A Randomized Controlled Trial

U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07755540) titled 'Group Music Therapy for Chronic Pain Management in Active Duty Service Members: A Randomize... Read More


Clinical Trial: Night Driving After Trifocal Versus Monofocal IOL Implantation

U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07755189) titled 'Night Driving After Trifocal Versus Monofocal IOL Implantation' on Aug. 05. Brief Summary:... Read More


Singapore Clinical Trial: A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

Singapore, Aug. 11 -- The Health Sciences Authority received information related to the study titled 'A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the ef... Read More


Clinical Trial: Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan

U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07755826) titled 'Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive T... Read More


Singapore Clinical Trial: A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

Singapore, Aug. 11 -- The Health Sciences Authority received information related to the study titled 'A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the ef... Read More